PHASE I STUDY OF CONTINUOUS INFUSION OF TOPOISOMERASE-1 INHIBITOR

拓扑异构酶 1 抑制剂连续输注的 I 期研究

• 批准号: 3849515
• 负责人: HOWARD HOCHSTER
• 金额: --
• 依托单位: NEW YORK UNIVERSITY
• 依托单位国家: 美国
• 资助国家: 美国
• 起止时间: 至
• 项目状态: 未结题
• 来源: https://reporter.nih.gov/project-details/3849515
• 关键词: DNA topoisomerases; antineoplastics; dosage; drug adverse effect; drug tolerance; enzyme inhibitors; human subject; intravenous administration; pharmacokinetics

This study will attempt to determine the qualitative and quantitative toxicities of topoisomerase-1 inhibitor, topotecan, when given by prolonged low-dose infusion and its maximally tolerated dose using this schedule. This study will also determine the pharmacokinetics and steady state levels achieved using this schedule and document any anti-tumor activity.

本研究将尝试确定定性和定量 拓扑异构酶 1 抑制剂拓扑替康 (topotecan) 长期给药时的毒性 使用此时间表的低剂量输注及其最大耐受剂量。 这项研究还将确定药代动力学和稳态水平 使用此时间表实现并记录任何抗肿瘤活性。